OraSure’s DNA Genotek Subsidiary Unveils First In-Home Self-Collection Device for Metabolomics
17 6월 2020 - 8:00PM
OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in
point-of-care diagnostic tests, specimen collection devices, and
microbiome laboratory and analytical services is introducing the
first and only commercially available device for in-home,
self-collection of fecal samples for metabolomics. A product of
OraSure’s DNA Genotek subsidiary, the OMNImet™·GUT (ME-200)
augments the Company’s portfolio of multiomic sample collection
products. The device is intended for research use only.
“Advances in the prediction, detection,
understanding, and monitoring of human diseases have increased the
use of metabolomics technologies,” said Kathleen Weber, Executive
Vice President, Business Unit Leader, Molecular Solutions at DNA
Genotek. “OMNImet™·GUT is designed to help scientists efficiently
unlock the complexity of the metabolome. It offers a breakthrough
design for self-collection and chemistry innovations that protect
metabolites in feces while ensuring sample integrity.”
Multiomics integrates data from multiple “omes”
(i.e., the genome, transcriptome, proteome, and metabolome) to
provide a more holistic view of human health, wellness and diseases
such as obesity, diabetes, Parkinson’s, autism and cancer.
The shift toward analytes beyond DNA is
occurring rapidly as life science researchers are increasingly
adopting a multiomic approach. Metabolites, which are the products
of metabolic activity within people’s bodies, are particularly
important because they help scientists understand the influences of
genes, microbiome, diet, life style and drug treatment on the state
of health and progression of disease.
Until now, the only option to study metabolites
in feces required immediate freezing and cold chain shipping of the
sample. DNA Genotek utilized its experience with sample collection
devices for genomics and microbiome to develop and validate a new
collection device and the stabilization chemistry necessary to
protect the sensitive nature of metabolites in feces and ensure
sample integrity. DNA Genotek collaborated with Metabolon, Inc.,
the metabolomics market leader, to validate the performance of the
OMNImet™·GUT collection device.
“OraSure is expanding its multiomic offerings by
deploying DNA Genotek’s technology to create and capture value from
multiple sample types and multiple analytes beyond nucleic acids,”
said Stephen S. Tang, Ph.D., President and Chief Executive Officer
of OraSure Technologies. “We believe that analyzing correlations
and causation across omes, now including the metabolome, will
present an integrative view of health that will yield dividends for
individual health, wellness, disease monitoring and treatment.”
The proprietary chemistry in the OMNImet™·GUT
device provides a minimum of seven days room temperature stability,
allowing donors to collect their sample at home and return it to
the laboratory within a reasonable timeframe while maintaining the
integrity of the sample for metabolomics analysis.
About OraSure Technologies
OraSure Technologies empowers the global community to improve
health and wellness by providing access to accurate, essential
information. Together with its wholly-owned subsidiaries, DNA
Genotek, Diversigen, CoreBiome (now operating under the Diversigen
brand) and Novosanis, OraSure provides its customers with
end-to-end solutions that encompass tools, services and
diagnostics. The OraSure family of companies is a leader in the
development, manufacture, and distribution of rapid diagnostic
tests, sample collection and stabilization devices, and molecular
services solutions designed to discover and detect critical medical
conditions. OraSure’s portfolio of products is sold globally to
clinical laboratories, hospitals, physician’s offices, clinics,
public health and community-based organizations, research
institutions, government agencies, pharma, commercial entities and
direct to consumers. For more information on OraSure Technologies,
please visit www.orasure.com.
About DNA GenotekDNA Genotek
Inc., a subsidiary of OraSure Technologies, Inc., focuses on
providing high-quality biological sample collection products and
end-to-end services for human genomics and microbiome applications.
The Company's Oragene®•Dx and ORAcollect®•Dx product lines are the
first and only FDA 510(k) cleared saliva-based DNA collection
devices for in vitro diagnostic use. DNA Genotek also offers
Research Use Only products to collect and preserve large amounts of
DNA or RNA from multiple sample types. DNA Genotek markets its
products worldwide and has a global customer base with thousands of
customers in over 100 countries. For more information about DNA
Genotek, visit www.dnagenotek.com
Investor Contact: |
Media Contact: |
Sam Martin |
Jeanne Mell |
Argot Partners |
VP Corporate Communications |
212-602-1902 |
484-353-1575 |
orasure@argotpartners.com |
media@orasure.com |
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 7월(7) 2024 으로 8월(8) 2024
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 8월(8) 2023 으로 8월(8) 2024